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Abstract
Background: Multiple Sclerosis (MS) is a neurodegenerative disease which runs its course for the
remainder of the patient's life frequently causing disability of varying degrees. Negative effects on
Health-related quality of life (HRQOL) are well documented and a subject of clinical study. The
Multiple Sclerosis QOL 54 (MSQOL-54) questionnaire was developed to measure HRQOL in
patients with MS. It is composed of 54 items, and is a combination of the SF-36 and 18 disease-
specific items.
Objective: The objective of this project was to translate the MSQOL-54 into French Canadian,
and to make it available to the Canadian scientific community for clinical research and clinical
practice.
Methods: Across all French speaking regions, there are occurrences of variation. They include the
pronunciation, sentence structure, and the lexicon, where the differences are most marked. For
this reason, it was decided to translate the US original MSQOL-54 into French Canadian instead of
adapting the existing French version. The SF-36 has been previously validated and published in
French Canadian, therefore the translation work was performed solely on the 18 MS specific items.
The translation followed an internationally accepted methodology into 3 steps: forward translation,
backward translation, and patients' cognitive debriefing.
Results: Instructions and Items 38, 43, 45 and 49 were the most debated. Problematic issues
mainly resided in the field of semantics. Patients' testing (n = 5) did not reveal conceptual problems.
The questionnaire was well accepted, with an average time for completion of 19 minutes.
Conclusion: The French Canadian MSQOL-54 is now available to the Canadian scientific
community and will be a useful tool for health-care providers to assess HRQOL of patients with
MS as a routine part of clinical practice. The next step in the cultural adaptation of the MSQOL-54
in French Canadian will be the evaluation of its psychometric properties.
Introduction
Multiple Sclerosis (MS) is a neurodegenerative disease
characterized by chronic inflammation, demyelination,
and scarring of the central nervous system. Symptoms
include weakness, fatigue, sensory loss, vertigo, lack of
coordination, impotence or sexual dysfunction, urinary
incontinence, optic atrophy, dysarthria, and mental prob-
lems [1,2]. The average age at onset of MS is 30 years, and
the disease runs its course for the remainder of the
patient's life frequently causing disability of varying
Published: 24 November 2003
Health and Quality of Life Outcomes 2003, 1:70
Received: 09 October 2003
Accepted: 24 November 2003
This article is available from: http://www.hqlo.com/content/1/1/70
© 2003 Acquadro et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all 
media for any purpose, provided this notice is preserved along with the article's original URL.Page 1 of 7
(page number not for citation purposes)
Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/70degrees [1]. The prevalence of MS varies with both geogra-
phy and ethnic background with women twice as likely to
be afflicted as men [3]. With an estimated 35,000 suffer-
ers, Canada is considered a high frequency area with an
average of between 55 and 202 per 10,000 persons [4].
While the effect of MS on life expectancy remains contro-
versial, the disease's negative effect on health-related qual-
ity of life (HRQoL) is documented and a topic currently
undergoing clinical study [5-7]. Several studies have
shown that HRQoL assessments provide unique informa-
tion not measured by the Kurtzke's Expanded Disability
Status Scale (EDSS), the commonly used outcome meas-
ure of impairment disability for MS patients [8-10]. As an
alternative indicators of the impact of the disease on a
patient's life, self-reported HRQoL focuses more attention
on MS patients as a whole, in addition to focusing on
physical problems [11,12].
From the perspective of patients' organizations and regu-
latory agencies HRQOL assessments are increasingly seen
as additional sources of information on the safety and
efficacy of treatments, particularly important in chronic
progressive, disabling diseases for which there is no cure
[13]. Although the main use of HRQoL instruments has
been in the context of clinical trials, the observation that
measures of patients' perception of their health do not
overlap with clinician assessments of disability reinforces
the importance of developing HRQoL instruments for use
in routine clinical practice [14,15]. Rothwell et al. have
shown that physical disability may not always be the main
determinant of overall health related quality of life. Fur-
thermore, their study showed that patient with MS are less
concerned than their clinicians about physical disability
in their illness [15]. Provinciali et al. have shown that
including HRQoL in their multidimensional assessment
protocol provides a detailed and sensitive evaluation of
patients' disability profile and perceived difficulties
thereby allowing clinicians to develop a care program tai-
lored to each individual's needs [16]. HRQoL measures
can also serve as screening instruments for patients report-
ing changes in symptom severity or functional ability. The
quality of life data can be used to involve patients and
family members in clinical decision-making [17].
The MSQOL-54 questionnaire was developed to measure
HRQoL in patients suffering from multiple sclerosis [18].
Composed of the Short Form 36 Item Health survey
(Short Form-36 or SF-36) [19,20] and 18 disease specific
items, this 54-item self-report measure combines the
strength of generic and disease specific approaches to
HRQoL measurement. By complementing the SF-36 with
questions focusing on the specific domains affected by MS
it becomes possible to compare the HRQOL of a patient
suffering from MS with the HRQoL of the general popula-
tion and the HRQOL of patients with other diseases. In
routine clinical practice the instrument could be used to
evaluate the differences in HRQoL of individuals at vari-
ous stages of MS.
The MSQOL-54 has been used in the United States and
has proven a valuable instrument for measuring HRQoL
in MS [21-23]. The questionnaire has also been translated
into both Italian [24] and French [25,26].
The objective of this study was to translate the MSQOL-54
into French Canadian, and to make it available to the
Canadian scientific community for clinical research and
clinical practice.
Methodology
Background
According to the Sapir-Whorf hypothesis [27], every lan-
guage embodies its own vision of the world, a prism
through which its speakers inevitably view, for instance,
their own health. If true, this hypothesis would indicate
that a valid translation is impossible. Fortunately, this is
not the case. We are in fact able to make the leaps of logic
necessary to comprehend the complex ideas put forth by
a foreign society [28], and translation techniques are
available to remove the difficulties hindering the optimal
transfer of the information, emotion, and stylistic content
of the original message [29].
Conducted using an internationally accepted methodol-
ogy, the cultural adaptation of an HRQoL questionnaire
encompasses two essential stages: a translation stage
ensuring linguistic validity of the questionnaire in the
new language and the evaluation of the psychometric
properties of the questionnaire or psychometric valida-
tion [30]. The two are complementary and indispensable
in demonstrating the equivalence between the original
and the translated questionnaires.
This paper describes the linguistic validation of the 18 MS
specific questions (i.e. #37 to #54) in French Canadian
since the SF-36 has been previously translated, psycho-
metrically validated and published in French Canadian
[31] and is currently used in the Canadian National Pop-
ulation Survey [32].
More than one hundred million people of very diverse
cultures speak French across the world. Quebec, the prin-
cipal French-speaking center in North America, consti-
tutes a significant member of this speech community. As
is the case for all languages, there are occurrences of vari-
ation inside the French language. The variation is compos-
ite: it includes the pronunciation (the accents), sentence
structure, and the lexicon, where the differences are most
marked [33]. For this reason we translated the 18 MSPage 2 of 7
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MSQOL-54 into French Canadian instead of adapting the
existing French version [26].
Linguistic validation
In general, there are four major stages (figure 1) involved
in a linguistic validation: forward translation, quality con-
trol through backward translation, test of understanding
or cognitive debriefing, international harmonization.
Each stage helps to improve the quality of the translation
in terms of the conceptual equivalence between the origi-
nal and translated questionnaires and the ease of under-
standing of the patient. In this project, the linguistic
validation of the 18 disease-specific questions of the
MSQOL-54 was performed solely into French Canadian
thereby removing the need for an International Harmoni-
zation process. The linguistic validation was carried out in
Canada by a Project Manager based in Canada, under the
supervision of Mapi Research Institute's Central Project
Manager based in Lyon France.
STEP 1: Forward Translation
The aim of this first step was to translate the 18 disease
specific questions (#37–54) of the original US MSQOL-54
questionnaire into French Canadian and produce a ver-
sion that was semantically and conceptually as close as
possible to the original questionnaire. Two qualified
translators, native speakers of French Canadian, proficient
in English and living in the target country, and the Local
French Canadian Project Manager, performed this step.
Each translator produced a forward translation of the orig-
inal instrument into the target language without mutual
consultation. The Local Project Manager reviewed the for-
ward translations, compared them with the original and
established a consensus version.
STEP 2: Backward Translation
Carried out with quality control in mind, the 18 French
Canadian questions generated in step 1 were translated
back into American English by one qualified translator,
native speaker of English, proficient in French Canadian
and living in Quebec. Following discussions between the
translator, the Local Project Manager, and Mapi Research
Institute's Central Project Manager, translation discrepan-
cies were corrected in the French version to generate a ver-
sion of the MSQOL-54 ready for testing by MS patients.
STEP 3: Cognitive Debriefing
The aim of this step was to check the French Canadian
population's understanding and interpretation of the
translated items and thereby validate the conceptual
equivalence between the US and French Canadian ver-
sions. The French Canadian version of the questionnaire
generated in step 2 was tested on five French Canadian
subjects with multiple sclerosis. This stage led to the final
French Canadian version of the MSQOL-54.
Results
What follows is an overview of the problems encountered
and the solving process. Minor changes made for typo-
graphical or grammatical reasons are not discussed.
Use of masculine/feminine forms
As both gender populations will use these questionnaires
both forms will be used in the translation wherever
appropriate.
Title: "Multiple Sclerosis Quality of life (MSQOL-54)
It was suggested that "Questionnaire de Qualité de vie sur
la sclérose en plaques" (Quality of Life Questionnaire on
multiple sclerosis) was not satisfactory as the notion of
"sur la sclérose en plaques" (on multiple sclerosis) was not
idiomatic. As a result of the discussions between the
French Canadian team and Mapi Research Institute it was
decided that "Questionnaire de Qualité de vie dans la
sclérose en plaques"(Quality of Life Questionnaire in
multiple sclerosis) was more understandable and more
accepted in spoken French Canadian.
Instructions
• First instruction sentence: "The survey asks you about
your health and daily activities"
In French Canadian it is impossible to use a literal trans-
lation of the verb "to ask" in this context because in spo-
ken French only a person can ask something of another
person, a survey cannot. After discussion with the French
Canadian consultant, it was decided to render "asks you
about" as "porte sur" (concerns), a much more idiomatic
verb in this sense.
• Second instruction sentence: "Answer every question
by ticking the appropriate statement"
As it is not idiomatic to use the verb "tick" in French Cana-
dian, it was decided to use "cocher" (cross), the usual way
to mark answers in this language.
• Third instruction sentence: " If you are unsure how to
answer a question, please give the best answer you can."
The notion "If you are unsure…" was initially translated
as " En cas d'hésitation…" (In case of hesitation…). How-
ever, subsequent to review and recommendation, it was
decided to change this to "En cas de doute…"(In case of
doubt…), as the French Canadian population more read-
ily understands it.Page 3 of 7
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Linguistic Validation – MAPI Research Institute process* *Adapted from: Mear I. Difficulties of international clini-
cal trials: Cultural adaptation of quality of life questionnaires. In Chassany O, Caulin C, eds. Health-related quality of 
life and Patient-reported outcomes: Scientific and useful outcome criteria. Paris: Springer Verlag Publishers, 2002; 55–62.
CONCEPTUAL
DEFINITION
Definition of the concepts underlying each item of the questionnaire 
Ø
Source questionnaire 
Ø
FORWARD
TRANSLATION
Production of two independent translations by two professional translators 
in the target language conducted in the target country 
Ø Reconciliation meeting between the two "forward" translators and the local 
project manager to obtain a consensus version. 
Forward version A1 
And
Forward version A2 
Quality control by the MAPI Research Institute 
Ø
Forward version B 
Ø
BACKWARD
TRANSLATION
Translation of forward version B into the source language by one 
independent translator 
Ø
Comparison of the source questionnaire with the "backward" translation by 
the local team to check the conceptual content of forward version B 
Forward version C Quality control by the MAPI Research Institute 
Ø
COGNITIVE
DEBRIEFING
 Interviews with patients/healthy subjects to test the interpretation of the 
translation
Quality control by the MAPI Research Institute 
Ø
Forward version D 
Ø
INTERNATIONAL
HARMONISATION
Comparison of the target language versions with each other and with the 
original to ensure conceptual equivalence during a meeting with 
professional translators representing all the countries involved 
Ø Quality control by the MAPI Research Institute 
Final version Final proof-reading Page 4 of 7
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• Item 38: "Were you discouraged by you health
problems?"
The item was originally translated as "Avez-vous été
découragé(e)…" (Have you been discouraged…). After
review, it was recommended to harmonize the structure of
this item with the one used in items 39 and 41 respec-
tively in order to maintain fluency in French Canadian.
Thus "Have you been discouraged…" was changed to
"Vous êtes-vous senti(e) découragé(e)… " (Have you felt
discouraged…).
• Item 40: "Was your health a worry in your life?"
This item was originally translated as "Did your health
worry you?" which is not equivalent to the original as the
notion of "in your life" was not included. Following the
backward translation step it was decided to reword the
question to include "dans votre vie" (in your life) to main-
tain the original documents intent and include a notion of
duration. As a result " Votre santé a-t-elle été un souci dans
votre vie?" (Has your health been a worry in your life?)
was adopted in French Canadian.
• Item 43: "Did you have trouble keeping attention on
an activity for long"
The original expression "keeping attention" was initially
translated to "se concentrer " (to concentrate). This form
was determined to be too restrictive since to concentrate is
an action with no notion of duration. After discussions
with the French Canadian consultant following the back-
ward translation step, it was decided to adopt "rester con-
centré(e) " (remain concentrated) to include the duration
factor.
• Item 45: "Have others, such as family members or
friends, noticed that you have trouble with your mem-
ory or problems with your concentration?"
The concept of "noticed" was initially translated as
"pointed out to you". During the backward translation
step it was determined that the original did not reflect the
notion that the family pointed this out to the patient and
was worded in such a way that the patient might have
heard these things indirectly or by chance. "Faire remar-
quer" (to point out) refers explicitly to a verbal exchange
between the patient and his/her family or friends, while
"remarquer" (remark, notice) simply refers to the fact that
the patient's friends or family noticed his/her problems
with memory but did not necessarily mention them to the
patient. It was therefore determined to replace the concept
of "faire remarquer" (pointed out) with "remarqué"
(noticed) following the backward translation step.
• Subtitle: "Sexual Function"
A literal translation was initially rendered but after Cogni-
tive debriefing the translation was deemed too technical.
As a result the French Canadian term "Vie Sexuelle" (Sex-
ual life) was adopted.
• Item 49: "Ability to satisfy sexual Partner"
The French Canadian team initially suggested translating
"ability" as "incapacity" given that items 46, 47, and 48
used negative wording to refer to sexual problems/dys-
functions. Item 46 refers to "lack of sexual interest", 47 to
"difficulty getting or keeping an erection/inadequate
lubrication, and 48 "difficulty having orgasm". Following
discussion between The Project Manager and Mapi
Research Institute, it was determined that use of the term
"incapacité" (incapacity) would carry a distinctly negative
connotation thereby discouraging the patients to rate abil-
ity even if the ability exists in a reduced form. "Incapacité"
was replaced by "capacité" (capacity) to better reflect the
original document and thus remain more neutral, and less
influential on patient's judgment of self.
Cognitive Debriefing
The French Canadian version of the MSQOL-54 was
tested on five French Canadian subjects with multiple
sclerosis. The mean age of the subjects was 51 years. Com-
pletion of the questionnaire took an average of 19 min-
utes. (See Table 1 for the data summary.)
Table 1: Cognitive debriefing subject data
CANADA (French) SEX AGE TIME (min) PROFFESSION PATHOLOGY
Subject 1 F 60 20 Accounts Clerk Multiple Sclerosis
Subject 2 M 51 18 Truck Driver Multiple Sclerosis
Subject 3 F 45 18 Housewife Multiple Sclerosis
Subject 4 F 47 23 Teacher Multiple Sclerosis
Subject 5 M 52 18 Building 
Superintendent
Multiple Sclerosis
Mean / 51 19.4Page 5 of 7
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was found to be clear, relevant, and appropriate to the
condition. The length of the questionnaire was acceptable
to the subjects with one exception who stated that the
questionnaire should not exceed its current length as
problems with concentration arose during the final phase
of completion.
No suggestions were made for missing articles or topics in
the questionnaire.The translated MSQOL-54 went
through cognitive debriefing successfully.
Conclusion
Health-related Quality of Life (HRQoL) questionnaires
are increasingly used in international clinical trials. The
cultural adaptation of an HRQoL questionnaire is a rigor-
ous and complex process [31,34]. The main objective is to
obtain a conceptual equivalence between the original and
translated versions, allowing, among other things, a pool-
ingand comparison of international studies data. This
incremental methodological approach has become essen-
tial as increasing amounts of data are collected about cul-
tural differences in measuring quality of life as well as the
different types of equivalence between cultures [35].
The translation of the MSQOL-54 in French Canadian was
carried out within the confines of internationally accepted
methodologies under the supervision of experts in the
field of cultural adaptation [29,30]. Instructions and
Items 38, 43, 45 and 49 were the most debated. Problem-
atic issues mainly resided in the field of semantics.
As suggested by Ware et al [20], HRQoL questionnaires
can form a practical tool for directly linking the norms
from large population surveys with the results from more
focused clinical trials, outcomes research studies, and
monitoring efforts in everyday clinical practice. Patients
have reported that information from assessments helped
guide discussions about treatment options and care plan-
ning, thereby improving communication with health care
providers [36]. It has been suggested in the extent litera-
ture on doctor-patient relationships that the clinical appli-
cation of HRQoL instruments helps to open the lines of
communication between doctors and patients [37]. It sig-
nals to the patient that his or her doctor is prepared to dis-
cuss a wide range of health related issues thereby allowing
them to relay details surrounding their condition that
might otherwise remain unspoken. In addition, these dis-
cussions help patients feel understood both physically
and emotionally. Of course, the use of HRQOL question-
naires can never substitute for the natural dynamics of
doctor-patient communication and interaction. It can,
however, be viewed as a valuable tool for structuring the
information gathering process. For these reasons, the
French Canadian MSQOL-54 can be considered as a use-
ful tool to help health-care providers to conduct formal
HRQoL assessments of patients with MS as a routine part
of clinical practice. Its proper use will necessitate the
adherence to a few basic guidelines: 1) the average time of
completion should not exceed 19 minutes, 2) the ques-
tionnaire may be administered directly in the waiting
room, 3) the integrity of the instruments' wording should
be maintained, 4) the patient's autonomy during comple-
tion process should be respected.
The next step in the cultural adaptation process of the
MSQOL-54 in French Canadian will be field research to
provide the empirical data necessary for its psychometric
evaluation.
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